Corcept Therapeutics Inc. (CORT) has a significant clinical trial catalyst this quarter related to its lead drug candidate, Relacorilant.
Relacorilant is a non-steroidal, selective glucocorticoid receptor modulator that is being evaluated in a variety of serious disorders, including Cushing's syndrome, ovarian cancer, and adrenal cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com